Popular Articles
Natural Remedies

Oncothyreon Announces Initiation Of Phase 3 Trial Of Stimuvax In Breast Cancer
Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.
generic viagra online
Malaria Cases Reported In Cambodian Public Facilities Drop More Than 50%
There was more than a 50 percent drop in the total number of malaria cases reported by public facilities in Cambodia between 2003 and 2008, according to the National Centre for Parasitology, Entomology and Malaria Control"s annual report, which was released on Tuesday, the Phnom Penh Post reports. Officials are attributing the decrease to village-based treatment and education programs.
News of the day
Prevention Does Not Necessarily Provide Expected Cost Savings
Senate Democrats and Obama administration officials hoping that preventive care would create federal savings have been disappointed to learn that it does not create expected cost savings.
Public Health

Studies Highlight A Revolutionary New Method Of Treating Post-Operative Bruising

Candela Corporation (NASDAQ: CLZR) announced that two studies have reported superior results on patients who benefited from the Candela Vbeam® laser treatments for bruising resulting from cosmetic procedures. The studies concluded that the Vbeam pulsed-dye laser significantly expedited the healing process, improved outcomes, and provided greater overall patient satisfaction. A study published in the March/April 2009 edition of the Archives of Facial Plastic Surgery, entitled: "Pulsed-Dye Laser for Treating Ecchymoses After Facial Cosmetic Procedures" by DeFatta, R. J., Krishna, S., and Williams, E. F., III concluded that "the Vbeam laser treatment resulted in a 63% mean improvement in ecchymoses scores within forty-eight (48) to seventy-two (72) hours." The second study, a 2009 ASLMS abstract, entitled: "A Simple Solution to a Common Problem" evaluated the effectiveness and safety of the long-pulse PDL (the Vbeam) for the treatment of ecchymoses. In this study by Elizabeth Hale, M.D., Julie Karen, M.D., Chris Hunzeker, M.D., Elliot Weiss, M.D., Leonard Bernstein, M.D., Lori Brightman, M.D., Anne Chapas, M.D., and Roy Geronemus, M.D. results showed that twenty-four hours post-treatment with the Vbeam laser, the average improvement was 62% and 13% for treated and untreated bruises, respectively. Edwin F. Williams, M.D., Director, The Williams Center Plastic Surgery Specialists, and nationally recognized plastic surgeon pioneered this breakthrough Vbeam treatment. "Anytime you penetrate the skin there is a potential for bruising and we find that it is the bruising which occurs after many of these procedures that prevents patients from getting out into the public. It is extremely difficult to cover these unsightly marks with make-up and bruising can last for a number of weeks," said Dr. Williams. Dr. Williams continued, "After just one treatment with the Vbeam, our patients experience dramatic clearance of the injured blood vessels. This treatment is a significant differentiator to our practice and we are excited to finally be able to offer our patients a safe and easy treatment of bruising that works!" Roy G. Geronemus, M.D., Director, Laser & Skin Surgery Center of New York, commented, "There are millions of surgical and injectable procedures performed every year which often have bruising as a side effect that can last up to two weeks." Dr. Geronemus continued, "This is a significant new use for the Vbeam which was already our "workhorse" laser because of its efficacy and safety profile for a wide variety of applications including skin rejuvenation, the treatment of rosacea, acne, diffuse redness, scars and more." CANDELA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):